Skip to main content
CRBP
NASDAQ Life Sciences

Corbus Pharmaceuticals Appoints Dr. Leonardo Nicacio as Chief Medical Officer with $2.1M Equity Grant

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$9
Mkt Cap
$171.382M
52W Low
$7.12
52W High
$20.56
52W Position info
26% above low
Off High info
56% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CRBP sits 26% above its 52-week low of $7.12.

Summary

Corbus Pharmaceuticals has appointed Dr. Leonardo Viana Nicacio as its new Chief Medical Officer, bringing significant oncology and ADC development expertise, supported by a substantial $2.1 million equity inducement award.


Key Events · Executive and Board Changes · CRBP

  • New Chief Medical Officer Appointed

    Dr. Leonardo Viana Nicacio has been appointed as Chief Medical Officer, effective August 3, 2026. He will receive an annual base salary of $545,000 and is eligible for an annual bonus of up to 40% of his base salary.

  • Significant Equity Inducement Award

    As a material inducement for employment, Dr. Nicacio will receive equity awards with an aggregate grant date fair value of $2,100,000, consisting of approximately 75% stock options and 25% restricted stock units.

  • Strategic Alignment with Oncology Pipeline

    Dr. Nicacio brings over 20 years of pharmaceutical industry experience, including a pivotal role in advancing the ADC TIVDAK® for metastatic cervical cancer, which is highly relevant to Corbus's lead oncology drug, CRB-701, an ADC targeting Nectin-4.

  • Upcoming Clinical Milestones

    The appointment comes as Corbus expects to initiate the TEMPO-1 registrational study of CRB-701 in 2L oropharyngeal squamous cell carcinoma (OPSCC) this summer, report topline findings from the CANYON-1 obesity study in late summer, and anticipate CRB-701 data in 1L OPSCC in early 2027.


Analysis · CRBP · Life Sciences

The appointment of Dr. Leonardo Viana Nicacio as Chief Medical Officer is a significant executive hire for Corbus Pharmaceuticals. His extensive background in solid tumor drug development and commercialization, particularly with antibody-drug conjugates (ADCs), directly aligns with the company's lead oncology program, CRB-701. The substantial equity inducement award of $2.1 million underscores the company's commitment to attracting top talent and incentivizing performance, especially as Corbus approaches critical clinical milestones for CRB-701 and CRB-913.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRBP was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.4M. The 52-week trading range was $7.12 to $20.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRBP - Latest Insights

CRBP
Nov 16, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $2.09 info
Change: -$1.36 (-39%) info
Market Cap: $42.45M info
CRBP
Nov 10, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $2.09 info
Change: -$1.43 (-41%) info
Market Cap: $42.45M info
CRBP
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.08
Real-time Price: $2.09 info
Change: -$4.99 (-70%) info
Market Cap: $42.45M info
CRBP
Sep 14, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $2.09 info
Change: -$7.17 (-77%) info
Market Cap: $42.45M info
CRBP
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.91
Real-time Price: $2.09 info
Change: -$6.82 (-77%) info
Market Cap: $42.45M info